Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

This publication has 43 references indexed in Scilit:

• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
  JNCI: Journal of the National Cancer Institute, 2009
• Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
  British Journal of Cancer, 2009
• Treatment in advanced colorectal cancer: what, when and how?
  British Journal of Cancer, 2009
• Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
  New England Journal of Medicine, 2009
• Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
  British Journal of Cancer, 2009
• Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
  New England Journal of Medicine, 2009
• K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
  New England Journal of Medicine, 2008
• CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
  Gut, 2008
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
  Annals of Oncology, 2008
• PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
  British Journal of Cancer, 2007